| Literature DB >> 31404285 |
Rodgers Norman Demba1,2, Nathan Shaviya3, Sylviah Mweyeli Aradi4, Walter Mwanda2.
Abstract
INTRODUCTION: Kaposi's sarcoma (KS) is a kind of cancer that causes flat or raised lesions containing Human herpes virus 8 (HHV8). The KS lesions are common among immunosuppressed HIV patients. Highly Active Antiretroviral (HHART) treats and prevents the development of KS. The objective of this study was to determine the presence of K1 and K15 (predominant alleles) genes in Kaposi's sarcoma-associated herpes virus (KSHV) among immunosuppressed patients due to HIV-1.Entities:
Keywords: KSHV; histology; nested PCR
Mesh:
Substances:
Year: 2019 PMID: 31404285 PMCID: PMC6675582 DOI: 10.11604/pamj.2019.32.215.17322
Source DB: PubMed Journal: Pan Afr Med J
Figure 1Microscopic identification of Kaposi's sarcoma (KS) and KS-like using H and E staining, X 20; (A) patch: patch stage Kaposi sarcoma showing vessels protruding into a larger vascular space characteristic of the promontory sign; (B) nodular: fascicles of relatively monomorphic spindled cells, with slit-like vascular channels containing erythrocytes; (C) plaque: plaque stage KS with bizarre vessels; there is erythrocyte extravasation and hemosiderin pigmentation; (D) KS-like: morphological feature suggestive of KS
Estimated of crude prevalence odds ratio (POR) using simple logistic regression for K1 and K15 (P) genes
| Characteristics | n (%) | K1 & K15 (P) gene positive n (%) | POR | 95% CI | P value |
|---|---|---|---|---|---|
| 0.57 | 0.14 - 2.31 | 0.428 | |||
| Male | 46(56.8) | 42(58.3) | |||
| Female | 35(43.2) | 30(41.7) | |||
|
| 1.07 | 0.99 – 1.18 | 0.104 | ||
| 18-29yrs | 9(11.1) | 7(9.7) | |||
| 30-39yrs | 39(48.1) | 34(47.2) | |||
| 40-49yrs | 23(28.4) | 21(29.2) | |||
| 50-59yrs | 6(7.4) | 6(8.3 | |||
| 60 yrs & above | 4(4.9) | 4(5.6) | |||
|
| 0.35 | 0.03- 3.75 | 0.377 | ||
| On ARVs | 77(95.1) | 69(95.8) | |||
| HAART naive | 4(4.9) | 3(4.2) | |||
|
| 1.0 | 0.25- 4.03 | 1.014 | ||
| >10 | 44(54.3) | 39(54.2) | |||
|
| 37(45.7) | 33(45.8) | |||
|
| 0.21 | 0.03- 1.76 | 0.152 | ||
| Generalized | 53(65.4) | 45(62.5) | |||
| Localized | 28(34.6) | 27(37.5) |
*Antiretrovirals (ARVs), Highly Active Antiretroviral Therapy (HAART), % (percentage), > above and < below